Subtopic Deep Dive
PARP Inhibitor Resistance Mechanisms
Research Guide
What is PARP Inhibitor Resistance Mechanisms?
PARP inhibitor resistance mechanisms are molecular processes including reversion mutations, drug efflux pumps, and reactivation of alternative DNA repair pathways that enable cancer cells to evade PARP inhibitor therapy.
These mechanisms counteract synthetic lethality in BRCA-mutated tumors by restoring homologous recombination or upregulating non-homologous end joining. Clinical observations show resistance emerging after initial responses to olaparib or niraparib (Fong et al., 2009; Moore et al., 2018). Over 10 key papers document patterns in ovarian, prostate, and pancreatic cancers.
Why It Matters
Resistance limits durable responses in BRCA-mutated cancers, reducing progression-free survival benefits from olaparib maintenance therapy (Moore et al., 2018; Golan et al., 2019). Identifying reversion mutations guides combination strategies with ATR inhibitors to block repair restoration. Understanding efflux pumps informs next-generation PARPi designs less prone to pumping, as seen in prostate cancer trials (Mateo et al., 2015; de Bono et al., 2020).
Key Research Challenges
Detecting Reversion Mutations
Reversion mutations restore BRCA function, reactivating homologous recombination and conferring resistance to olaparib (Fong et al., 2009). Sequencing resistant tumors reveals these frameshift corrections, but low-frequency variants challenge detection (Pritchard et al., 2016). Clinical trials show higher incidence in progressed prostate cancers (Mateo et al., 2015).
Drug Efflux Pump Upregulation
ABC transporters expel PARPi from cells, reducing intracellular concentrations and efficacy (Murai et al., 2012). Resistance emerges in ovarian cancer patients post-niraparib maintenance (Mirza et al., 2016). Pump inhibitors combined with PARPi show preclinical promise but lack clinical validation.
Alternative Repair Pathway Reactivation
Shift to non-homologous end joining or microhomology-mediated repair bypasses PARPi trapping (Murai et al., 2012). This occurs in BRCA-wildtype tumors and post-treatment adaptations (Kaufman et al., 2014). Combination with CHK1 inhibitors targets these pathways in resistant models.
Essential Papers
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · 2009 · New England Journal of Medicine · 3.6K citations
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NC...
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · 2018 · New England Journal of Medicine · 2.7K citations
The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation,...
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · 2016 · New England Journal of Medicine · 2.4K citations
Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receivin...
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · 2015 · New England Journal of Medicine · 2.1K citations
Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. (...
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · 2020 · New England Journal of Medicine · 2.1K citations
In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recomb...
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
Talia Golan, Pascal Hammel, Michele Reni et al. · 2019 · New England Journal of Medicine · 2.1K citations
Among patients with a germline <i>BRCA</i> mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and ot...
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai, Shar-yin N. Huang, Benu Brata Das et al. · 2012 · Cancer Research · 2.1K citations
Abstract Small-molecule inhibitors of PARP are thought to mediate their antitumor effects as catalytic inhibitors that block repair of DNA single-strand breaks (SSB). However, the mechanism of acti...
Reading Guide
Foundational Papers
Start with Fong et al. (2009, 3582 citations) for initial PARPi efficacy in BRCA carriers where resistance later emerges; Murai et al. (2012, 2093 citations) explains trapping mechanism central to resistance; Kaufman et al. (2014, 1651 citations) details monotherapy responses preceding resistance.
Recent Advances
Moore et al. (2018, 2683 citations) on olaparib maintenance with resistance implications in ovarian cancer; de Bono et al. (2020, 2114 citations) shows progression in prostate cancer despite HR defects; Golan et al. (2019, 2107 citations) in pancreatic cancer.
Core Methods
PARP trapping assays (Murai et al., 2012); genomic sequencing for reversion mutations (Pritchard et al., 2016); loss-of-heterozygosity analysis for HRD (Abkevich et al., 2012); progression-free survival tracking in trials (Mirza et al., 2016).
How PapersFlow Helps You Research PARP Inhibitor Resistance Mechanisms
Discover & Search
Research Agent uses citationGraph on Fong et al. (2009, 3582 citations) to map resistance-related progeny papers, then exaSearch for 'PARPi reversion mutations ovarian cancer' to uncover 50+ studies on BRCA restoration.
Analyze & Verify
Analysis Agent applies readPaperContent to Murai et al. (2012) for PARP trapping details, then runPythonAnalysis to quantify mutation frequencies from supplementary data using pandas, with GRADE grading for evidence strength and verifyResponse (CoVe) for resistance mechanism claims.
Synthesize & Write
Synthesis Agent detects gaps in combination therapies via contradiction flagging across Moore et al. (2018) and Mirza et al. (2016), then Writing Agent uses latexSyncCitations and latexCompile to generate a review section with exportMermaid diagrams of repair pathway shifts.
Use Cases
"Extract and plot BRCA reversion mutation frequencies from resistant tumor sequencing data in PARPi trials."
Research Agent → searchPapers('BRCA reversion PARPi resistance') → Analysis Agent → readPaperContent(Pritchard 2016) → runPythonAnalysis(pandas parse variants.csv, matplotlib frequency plot) → researcher gets publication-ready figure with stats.
"Draft LaTeX review on efflux pump mechanisms in niraparib resistance."
Research Agent → findSimilarPapers(Mirza 2016) → Synthesis Agent → gap detection → Writing Agent → latexEditText('efflux section'), latexSyncCitations([Mirza2016, Murai2012]), latexCompile → researcher gets compiled PDF with synced references.
"Find GitHub repos analyzing PARPi trapping simulations from Murai 2012."
Research Agent → searchPapers('PARP trapping Murai') → Code Discovery → paperExtractUrls(Murai2012) → paperFindGithubRepo → githubRepoInspect → researcher gets runnable simulation code for resistance modeling.
Automated Workflows
Deep Research workflow scans 50+ papers from Fong et al. (2009) citationGraph, structures resistance mechanisms report with GRADE scores. DeepScan's 7-step chain verifies reversion claims in Mateo et al. (2015) via CoVe checkpoints and Python survival analysis. Theorizer generates hypotheses on ATR/PARPi combinations from pathway data in Murai et al. (2012).
Frequently Asked Questions
What defines PARP inhibitor resistance mechanisms?
Molecular adaptations like BRCA reversion mutations, efflux pumps, and alternative DNA repair reactivation that restore cancer cell survival under PARPi treatment (Fong et al., 2009; Murai et al., 2012).
What methods identify resistance in patients?
Tumor sequencing detects reversion mutations; genomic loss of heterozygosity patterns predict HR defects (Abkevich et al., 2012); clinical progression post-olaparib tracks resistance (Moore et al., 2018).
What are key papers on PARPi resistance?
Fong et al. (2009, 3582 citations) first showed olaparib activity in BRCA carriers with emerging resistance; Murai et al. (2012, 2093 citations) detailed PARP trapping; Pritchard et al. (2016) quantified DNA-repair mutations in prostate cancer.
What open problems remain in resistance research?
Validating combination therapies blocking alternative repairs; developing pump-resistant PARPi; predicting resistance pre-treatment via biomarkers beyond BRCA status (Mirza et al., 2016; de Bono et al., 2020).
Research PARP inhibition in cancer therapy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching PARP Inhibitor Resistance Mechanisms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the PARP inhibition in cancer therapy Research Guide